Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
82.15
+4.46 (5.74%)
At close: Mar 6, 2026
SHA:688266 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | - | 2,154 | 2,110 | 797.05 | 1,137 |
Trading Asset Securities | - | 40.5 | 137.02 | 248.93 | 65.26 |
Cash & Short-Term Investments | 2,086 | 2,194 | 2,247 | 1,046 | 1,202 |
Cash Growth | -4.91% | -2.34% | 114.79% | -12.97% | -24.86% |
Accounts Receivable | - | 143.63 | 101.14 | 88.99 | 62.37 |
Other Receivables | - | 9.38 | 10.89 | 12.51 | 12.45 |
Receivables | - | 153.01 | 112.03 | 101.5 | 74.82 |
Inventory | - | 182.86 | 110.85 | 98.98 | 51.91 |
Other Current Assets | - | 45.85 | 50.79 | 45.3 | 77.33 |
Total Current Assets | - | 2,576 | 2,520 | 1,292 | 1,406 |
Property, Plant & Equipment | - | 363.43 | 271.21 | 247.09 | 188.91 |
Long-Term Investments | - | - | 5.99 | 10 | 10 |
Other Intangible Assets | - | 50.01 | 69.27 | 91.03 | 116.29 |
Long-Term Deferred Charges | - | 11.39 | 16.39 | 20.96 | 13.03 |
Other Long-Term Assets | - | 3.88 | 4.02 | 7.48 | 11.78 |
Total Assets | - | 3,005 | 2,887 | 1,668 | 1,746 |
Accounts Payable | - | 197.1 | 137.73 | 151.72 | 118.19 |
Accrued Expenses | - | 86.22 | 82.02 | 67.5 | 48.22 |
Short-Term Debt | - | 951.86 | 795.16 | 390.79 | 131.81 |
Current Portion of Long-Term Debt | - | 4.97 | 50.56 | 50.04 | 30.03 |
Current Portion of Leases | - | 11.2 | 13.17 | 13.69 | 13.55 |
Current Income Taxes Payable | - | 20.95 | 20.64 | 20.29 | 18.58 |
Current Unearned Revenue | - | - | - | 0.28 | 0.36 |
Other Current Liabilities | - | 101.15 | 35.89 | 34.88 | 20.16 |
Total Current Liabilities | - | 1,373 | 1,135 | 729.19 | 380.89 |
Long-Term Debt | - | 44.35 | - | 50.09 | - |
Long-Term Leases | - | 26.86 | 29.46 | 43.18 | 48.18 |
Long-Term Unearned Revenue | - | 9.2 | 11.55 | 45.04 | 48.05 |
Long-Term Deferred Tax Liabilities | - | 5.7 | 9.58 | 13.32 | 15.77 |
Other Long-Term Liabilities | - | 292.45 | 56.6 | - | - |
Total Liabilities | - | 1,752 | 1,242 | 880.82 | 492.88 |
Common Stock | - | 264.71 | 264.71 | 240 | 240 |
Additional Paid-In Capital | - | 3,120 | 3,353 | 2,222 | 2,205 |
Retained Earnings | - | -2,117 | -1,979 | -1,700 | -1,243 |
Comprehensive Income & Other | - | -14.47 | -5.95 | -2.84 | -6.32 |
Total Common Equity | 1,149 | 1,254 | 1,633 | 759.12 | 1,196 |
Minority Interest | - | -1.26 | 11.98 | 28.37 | 56.76 |
Shareholders' Equity | 1,149 | 1,253 | 1,645 | 787.49 | 1,253 |
Total Liabilities & Equity | - | 3,005 | 2,887 | 1,668 | 1,746 |
Total Debt | 1,126 | 1,039 | 888.35 | 547.8 | 223.57 |
Net Cash (Debt) | 960.79 | 1,155 | 1,358 | 498.18 | 978.32 |
Net Cash Growth | -16.81% | -14.97% | 172.65% | -49.08% | -36.78% |
Net Cash Per Share | 3.65 | 4.36 | 5.31 | 2.08 | 4.08 |
Filing Date Shares Outstanding | 264.71 | 264.71 | 264.71 | 264.49 | 240 |
Total Common Shares Outstanding | 264.71 | 264.71 | 264.71 | 240 | 240 |
Working Capital | - | 1,202 | 1,385 | 562.57 | 1,025 |
Book Value Per Share | 4.34 | 4.74 | 6.17 | 3.16 | 4.98 |
Tangible Book Value | 1,114 | 1,204 | 1,564 | 668.09 | 1,080 |
Tangible Book Value Per Share | 4.21 | 4.55 | 5.91 | 2.78 | 4.50 |
Buildings | - | 135.26 | 41.93 | 41.93 | 41.21 |
Machinery | - | 145.53 | 120.48 | 121.74 | 96.02 |
Construction In Progress | - | 123.47 | 135.83 | 86.67 | 27.25 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.